Introduction
============

Chronic myeloid leukemia (CML) is unequivocally distinguishable from other myeloproliferative disorders by the presence of a reciprocal translocation of chromosomes 9 and 22 ([@b1-ijo-49-03-0913]--[@b3-ijo-49-03-0913]). Although the Philadelphia chromosome is detected in 90--95% of CML patients, evidence of the BCR-ABL rearrangement is also usually detected in the subgroup of Philadelphia chromosome-negative CML patients ([@b4-ijo-49-03-0913]--[@b6-ijo-49-03-0913]).

The presence of BCR-ABL in CML patients and the requirement of kinase activity for BCR-ABL function make this an attractive target for selective kinase inhibitors.

The old traditional therapy of newly diagnosed chronic phase-CML patients includes busulfan and hydroxyurea and most of the patients will stay in a chronic phase for approximately 3--5 years ([@b7-ijo-49-03-0913],[@b8-ijo-49-03-0913]). Treatment of CML later evolved to where the goal was prolongation of the chronic phase through induction of karyotypic remission and possibly molecular remission using Alfa-interferon therapy with or without cytosine arabinoside. Thereafter, imatinib mesylate (IM) a tyrosine kinase inhibitor (TKI) was introduced as potential molecular therapy for CML ([@b7-ijo-49-03-0913],[@b9-ijo-49-03-0913]). IM is capable of inhibiting BCR-ABL kinase activity by blocking ABL tyrosine kinase action through the binding and subsequent inactivation of the ATP-binding sites of ABL tyrosine kinase in leukemic cells ([@b9-ijo-49-03-0913],[@b10-ijo-49-03-0913]). Since its introduction, several clinical trials have demonstrated the efficacy of IM and new generation TKIs in the treatment of CML, including patients with interferon-refractory CP-CML, as well as patients with CML in blast crisis ([@b11-ijo-49-03-0913]).

Approximately more than 50% of CML patients treated with imatinib achieve a complete cytogenetic response ([@b11-ijo-49-03-0913],[@b12-ijo-49-03-0913]). CML progression while on imatinib is usually due to the emergence of imatinib-resistant BCR-ABL mutant cells.

The relatively unpredictable biological behavior is a major challenge in its management as the chronic phase of CML is less aggressive and has very favorable prognosis with an excellent 5-year survival rate. By contrast, the biologically aggressive blast phase of CML is often rapidly fatal ([@b2-ijo-49-03-0913]). Currently, there is no recognized prognostic value for the baseline BCR-ABL level, furthermore, there are variations in sensitivity or dependability of RQ-PCR assays across different laboratories ([@b13-ijo-49-03-0913]). There is therefore a need to develop molecular markers for selection of choice of therapy at the time of diagnosis and to identify patients that are more likely to achieve a sustained remission, and patients who are more likely to develop resistance to imatinib therapy.

New analytical tools in proteomics are emerging that give new insights into biological processes that may speed up the discovery of potential biomarkers. Quantitative molecular variations may be used for the development of methods for tumor classification based on large amounts of gene expression data generated by 2-DE analysis of proteins ([@b14-ijo-49-03-0913],[@b15-ijo-49-03-0913]).

The main aim of the present study is towards discovery of objective markers that predict patients' response status and selection of appropriate choice of therapy at the onset of disease diagnosis. It focuses on the analysis of global peripheral blood plasma and bone marrow plasma protein expression profiles among CP-CML patients who achieved LT-MMR on imatinib compared with patients without MMR as well as whether or not they remain on TKI or switch to second generation TKI or requiring alternative therapy.

The endpoint is to identify disease-specific/disease-associated protein biomarkers seen in bone marrow tissue as well as in peripheral blood plasma. This would subsequently allow monitoring of such biomarker proteins in peripheral blood, rather than bone marrow, demanding less invasive procedures for objective prediction of individual's best treatment options and prognostic monitoring of CML patients.

Materials and methods
=====================

All bone marrow samples were obtained by aspiration procedure via posterior iliac crest under local anesthesia*.* Because of limited amount of materials for analysis, the cells were not flow cytometry sorted, rather unsorted bone marrows as well as unsorted peripheral blood plasma were collected and prepared for analysis.

Bone marrow and plasma, samples obtained at diagnosis and prior to initiation of treatment from 37 patients with newly diagnosed CP-CML were subjected to expression proteome analysis using combined gel-based 2-DE and label-free in-solution quantitative liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Patients selections into those that achieved or did not achieve MMR was based on patients with serial positive or negative responses to treatment at different time-points (3, 6, 12 and 24 months, respectively). Patients that responded at a time-point but failed to respond at the next time-point were not included in the analysis. However, patients that did not achieve MMR at 3 months, but subsequently achieved MMR at 6, 12 and 24 months were included. Because there was fewer number of patients with MMR at 3 months, the focus of our analyzed time-points were at 6, 12 and 24 months. Twenty-five patients consisting 13 with major molecular response and 12 without major molecular response were analyzed. In addition, patients that failed tyrosine kinase inhibitor (TKI) were analyzed. Four additional patients samples not included in the proteomics analysis were used in the western blot analysis. The overview of experimental design is shown in [Fig. 1](#f1-ijo-49-03-0913){ref-type="fig"} and the clinical characteristics of all patients were as indicated in [Table I](#tI-ijo-49-03-0913){ref-type="table"}.

Sample preparation protocols for proteomic analysis
---------------------------------------------------

All the patients with primary diagnosis of CML were recruited in Oncology Center at KFSH&RC. From each of the patients, 10 ml of peripheral EDTA-anti-coagulated blood (plasma) was taken. Where possible, bone marrow aspirations were obtained from the same patients in addition to peripheral blood samples.

All samples were subjected to extensive pre-analysis cleanup using human albumin removal protocols (Agilent Technologies). Written and signed informed consents were obtained from all patients and the Institution's Research Advisory Council, under the Office of Research Affairs, approved the study (RAC\# 2050-040).

Protein separation by high resolution two dimensional gel electrophoresis, (2-DE) scanning and image analysis
-------------------------------------------------------------------------------------------------------------

Equivalent amount of 50 mg total proteins for each analyzed sample was dissolved in 350 ml volume of rehydration buffer \[2% (v/v) IPG-buffer 4--7 linear\] and loaded onto an 11-cm IPG-strip 4--7 linear (Bio-Rad Laboratories). This gave better overview of gel separated protein spots across the entire chosen pH window and gel images were visualized by SYPRO Ruby fluorescent staining. Stained gels were scanned using a Typhoon Trio Imager (GE) and data were analyzed using the Progenesis SameSpots software (version 7.1.0; Nonlinear Dynamics, Ltd., Newcastle, UK). Gel images were compared for qualitative and quantitative differences. In addition, the protein expression profiles were used to assess the level of individual variability and only samples with similar phenotypic changes were used for sample pools for LC/MS/MS (due to low through-put analysis) as detailed below. Polypeptide quantities were calculated based on the normalized total integrated density volume.

Protein in solution-digestion
-----------------------------

The plasma samples were diluted and protein concentrations of all samples were normalized as previously described ([@b16-ijo-49-03-0913]). Briefly, for analytical runs, equal amount of protein was taken from each sample to generate a pool of patient as one group. The samples within same sample cohort were pooled due to low through-put of LC/MS/MS analysis platform. However, samples were initially screened using 2-DE for homogeneity within the same analysis group. For each analysis sample group, 200 μg complex protein mixture was taken and exchanged twice with 500 μl of 0.1% RapiGest (Waters Corp., Manchester, UK). Protein concentrations of between 0.50 and 1 μg/μl was achieved at the end of digestion. Details of digestion protocols are as previously described ([@b16-ijo-49-03-0913],[@b17-ijo-49-03-0913]). Briefly, proteins were denatured in 0.1% RapiGest SF at 80°C for 15 min, reduced in 10 mM DTT at 60°C for 30 min, and alkylated in 10 mM Iodoacetamide (IAA) for 40 min at room temperature in the dark. Samples were trypsin digested at 37°C overnight. Samples were diluted with aqueous 0.1% formic acid prior to LC/MS analysis in order to achieve a load of \~2 μg on analytical column. All samples were spiked with yeast alcohol dehydrogenase (ADH; P00330) as internal standard to the digests in order for absolute quantitation.

Protein identification by mass spectrometry: LC-MSE analysis
------------------------------------------------------------

The digested peptides were subjected to 1-Dimensional Nano Acquity liquid chromatography coupled with tandem mass spectrometry on Synapt G2 (Waters Corp.). Expression proteomics data were generated between sample groups using both qualitative and quantitative protein changes. The ESI-MS analysis and instrument settings were optimized on the tune page as previously reported ([@b16-ijo-49-03-0913]).

A total of 2 μl sample injection representing \~1 μg protein digests was loaded on-column and samples were infused using the Acquity sample manager with mobile phase consisting of A1 99% water +1% acetonitrile + 0.1% formic acid and B1 acetonitrile + 0.1% formic acid with sample flow rate of 0.450 μl/min. Data acquisition using iron mobility separation experiments (HDMSE) were performed and data were acquired over a range of m/z 50--2000 Da with a total acquisition time of 115 min. All samples were analyzed in triplicate runs (triplicate runs were repeated on two different occasions as a measure of reproducibility) and data were acquired using the MassLynx programs (version. 4.1, SCN833; Waters) operated in resolution and positive polarity modes. ProteinLynx Global Server (PLGS) 2.2 and Progenesis QI for proteomics (Progenesis QIfp version 2.0.5387) (Nonlinear Dynamics/Waters) were used for all automated data processing and database searching. The generated peptide masses were searched against two-unified non-redundant databases (Uniprot/Swiss-Prot Human protein sequence database) using the PLGS 2.5 and Progenesis QIfp for protein identification (Waters).

Data analysis and informatics
-----------------------------

Progenesis QI v.2.0.5387 for proteomics was used to process and search the data to accurately quantify and identify proteins that are significantly changing between sample groups. The human database containing thousands of reviewed non-redundant entries were downloaded from UniProt/Swiss-Prot and search algorithm was applied as previoudly described ([@b18-ijo-49-03-0913]). The criteria used for the database search were as previously described ([@b16-ijo-49-03-0913]). Normalized label-free quantification was achieved using Progenesis QI software. The generated differentially expressed data was filtered to show only statistically (ANOVA), significantly regulated proteins (P≤0.05) and a fold change \>1.5. In addition, 'Hi3' absolute quantification was performed using ADH as an internal standard to give an absolute amount of each identified protein. These options are available as incorporated into the Progenesis QIfp (Nonlinear Dynamics/Waters).

Results
=======

Changes in protein expression between patients with/without major molecular response at 6 months
------------------------------------------------------------------------------------------------

A total of 73 protein spots on 2-DE gels differed significantly between patients that achieved MMR from those who did not achieve MMR (P\<0.05 and at least 1.5-fold difference). The locations of these protein spots are shown as marked on a representative 2-DE map derived from a sample with MMR in [Fig. 2A](#f2-ijo-49-03-0913){ref-type="fig"}. Even though the identifications of these protein spots were not done, their quantitative expression fingerprints from 2-DE analysis pattern accurately predicts 13 individuals that achieved MMR at 6 months from 12 subjects without MMR (No-MMR) using principal component analysis (PCA) ([Fig. 2B](#f2-ijo-49-03-0913){ref-type="fig"}).

These findings are similar to what was observed with PCA plot generated from non-gel LC/MS/MS analysis platform, as some of the results were independently validated using the label free quantitative liquid chromatography tandem mass spectrometry as detailed below.

LC/MS/MS analysis of peripheral blood for prognostic monitoring of early CML treatment response
-----------------------------------------------------------------------------------------------

Peripheral blood samples were evaluated for early treatment response at 6 month and prediction of treatment options towards personalized medicine. Approximately 115 protein species were identified, of which only 64 were significantly differentially expressed between MMR and No-MMR sample groups. (\> 1.5- to ∞-fold change, p\<0.05). These proteins predict accurately patients with MMR vs. No-MMR patients using unsupervised Hierarchical Cluster Analysis ([Fig. 3](#f3-ijo-49-03-0913){ref-type="fig"}).

Evaluation of bone marrow and peripheral blood protein profiles for prognostic monitoring of prolonged and sustained treatment response vs. persistent no-major molecular response
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Some of the patients have been followed for more than 24 months. Patients who have been consistent over a long-term in achieving and maintaining MMR from 6 months until 24 months were labeled as LT-MMR, while patients that have been persistent with No-MMR from 6 months until 24 months were called P-No-MMR. We believe that the ability to select early responders from 6 months all through 24 months would be very helpful to identify markers that would accurately predict patients with risk of delayed or suboptimal response further than 6 months. These cohorts of patients were considered as important in an effort to provide the possibility to identify surrogate biomarkers to evaluate long-term treatment response and discovery of disease-specific/disease-associated proteins for objective prognostic monitoring of CML patients.

Equal amounts of total peripheral blood plasma proteins from 10 LT-MMR patients were pooled and compared for their protein expressions among 10 other samples from P-No-MMR patients using quantitative label-free LC/MS/MS expression proteome analysis.

Approximately 700 proteins representing 280 unique protein species were identified (due to different protein isoforms). Only 164 of the 280 proteins were significantly differentially expressed between LT-MMR and P-No-MMR sample groups (\>1.5- to ∞-fold change; P\<0.05) and accurately predict patients with major molecular response (LT-MMR) vs. No-major molecular response (P-No-MMR) using unsupervised principal component analysis ([Fig. 4A](#f4-ijo-49-03-0913){ref-type="fig"}). The list of identified differentially expressed proteins in PBP is described in [Table IIA](#tII-ijo-49-03-0913){ref-type="table"}.

Similar to peripheral blood samples, \>700 proteins representing 250 unique protein species were identified when similar analysis was done on bone marrow pooled samples from 8 LT-MMR patients and 8 P-No-MMR patients. One hundred and thirty-eight of the total identified proteins were significantly differentially expressed between LT-MMR and P-No-MMR bone marrow sample groups (\>1.5- to ∞-fold change, P\<0.05; [Table IIB](#tII-ijo-49-03-0913){ref-type="table"}). These proteins predict accurately LT-MMR patients vs. P-No-MMR patients using unsupervised principal component analysis ([Fig. 4B](#f4-ijo-49-03-0913){ref-type="fig"}). These results were subsequently evaluated for comparisons with the patterns obtained in early treatment response at 6 months. Notably, the pattern and accuracy of clustering of samples is very similar to that observed with the hierarchical cluster analysis plots at 6 months ([Fig. 3](#f3-ijo-49-03-0913){ref-type="fig"}).

Protein fingerprinting for prediction of treatment options for individualized therapy
-------------------------------------------------------------------------------------

Towards achieving the goal of personalized medicine, the above observed differentially expressed proteins between samples derived from LT-MMR patients vs. P-No-MMR patients were evaluated for their potential for objective prediction of treatment options for some of these cohorts of CML patients. Interestingly, the panel of 164 and 138 differentially expressed protein datasets derived from peripheral blood plasma (PBP) and bone marrow (BM) respectively, also discriminates patients that stay on IM after 1 year of treatment from patients that ultimately required alternative treatment options (second generation TKI/others) ([Fig. 5](#f5-ijo-49-03-0913){ref-type="fig"}). Following \>2 years of follow-up of these patients the same dataset of potential protein biomarkers could still accurately separate all analyzed sample groups into their respective molecular response and treatment sub groups, indicating their usefulness for treatment monitoring as well as prediction of best choice of therapy for individual patient. Some of the identified proteins were implicated in hematological diseases as potential biomarkers using ingenuity pathway analysis (IPA) ([Fig. 6](#f6-ijo-49-03-0913){ref-type="fig"}). Functional annotations/disease affiliations of some of these proteins implicated in CML are further described under discussion below.

Identification of protein changes in BM as a reflection of detectable changes in peripheral blood
-------------------------------------------------------------------------------------------------

One of the main goals of this study was to identify/develop disease-specific/disease-associated protein biomarkers seen in bone marrow tissue as well as in peripheral blood plasma. This would subsequently allow monitoring of such biomarker proteins in peripheral blood, rather than bone marrow, demanding less invasive procedures for objective prediction of individual's best treatment options and prognostic monitoring of CML patients. We therefore explored the possibility whether the proteins that are significantly differentially expressed in bone marrow do also show similar expression pattern in peripheral blood. With this in mind, we calculated how many of the 164 differentially expressed proteins in peripheral blood and the 138 protein dataset in bone marrow are common to both body compartments. We found that only 54 proteins (\~35%) were in common between the two 164 and 138 datasets as described above. This set of 54 proteins was then subjected to unsupervised hierarchical clustering and correspondence analyses. As shown in [Fig. 7](#f7-ijo-49-03-0913){ref-type="fig"}, all sample groups were distinctively separated into four response subtypes using unsupervised hierarchical cluster analysis. The common proteins between the two body fluid compartments were highlighted in bold in [Table II](#tII-ijo-49-03-0913){ref-type="table"}.

Validation by western blot analysis of some of the identified proteins
----------------------------------------------------------------------

In an attempt to validate some of the differentially expressed proteins, we have used immunoblotting analysis. Nine individual samples consisting of 4 samples not included in the proteomics analysis and 5 other samples from the proteomics analyzed sample groups were tested for their expression of haptoglobin and hemoglobin using specific antibodies against these proteins. The expression levels of these proteins across all sample groups were consistent with the average protein normalized levels seen with label-free quantitative LC/MS/MS analysis ([Fig. 8](#f8-ijo-49-03-0913){ref-type="fig"}). Large scale validation of the majority of these proteins was beyond the scope of this study in order to develop limited panel of markers for clinical trial in a later study.

Discussion
==========

Clinical and molecular diagnosis of most hematological malignancies including CML can be accurately made; however, prediction of treatment response elude the currently available tools for patient care.

A subset of significantly differentially expressed proteins from both peripheral blood and bone marrow were selected for their ability to discriminate samples derived from CML patients that responded differently to initial first line treatment with imatinib. Our strategy of proteomics mining of BM and PBP from the same individual patient would provide unique possibility to identify biomarkers from both sources thus, entailing less invasive procedures.

Report of microarray analysis of peripheral blood and bone marrow of CML samples in blast crisis cells, has been shown with demonstrable biological changes between two bodily fluids ([@b19-ijo-49-03-0913]). Our analysis of peripheral blood samples of 164 differentially expressed proteins show that all samples were correctly classified and similar result was observed with 138 protein changes in bone marrow samples as shown in [Fig. 4](#f4-ijo-49-03-0913){ref-type="fig"}. Only 54 proteins were shown to be commonly differentially expressed between blood dataset and bone marrow protein dataset in the present study, supporting our notion that it might be possible to identify significant changes in the bone marrow of CML patients that are measurable at peripheral blood compartment for routine diagnostics.

We have attempted to use both the BMP and PBP data-sets that accurately predict patients MMR status for possible prediction of patients that continue to stay on IM after 1 year of treatment vs. those that ultimately required alternative treatment options (second generation TKI/others). Thus, the expression of the 158 protein changes in BM between MMR and No-MMR were further evaluated in 16 unrelated patients that stay on TKI after 1 year of imatinib treatment from patients that ultimately required alternative treatment options (second generation TKI/others). We found four distinct clusters with samples with MMR and No-MMR being very closely separated (not as distinct as in [Fig. 4](#f4-ijo-49-03-0913){ref-type="fig"}), while patients that stay on TKI (i.e. after 1 year of imatinib) treatment were distantly separated from patients that ultimately required alternative treatment options (second generation TKI/others) as shown in [Fig. 5](#f5-ijo-49-03-0913){ref-type="fig"}, meaning that it will be challenging to construct a universal model for management of CML patients and that prognostic datasets need to be created for each specific response type.

We have used two independent proteomics analysis platforms in the present study. The expression profiles of 2-DE protein spots successfully discriminated two sample groups of CML patients with MMR and No-MMR. We recognized the inherent limitation of 2-DE based studies ([@b20-ijo-49-03-0913]--[@b22-ijo-49-03-0913]) hence, we have in addition used label-free quantitative protein expression using high definition liquid chromatography tandem mass spectrometry (LC/MS/MS) to extensively map the proteome of bone marrow as well as peripheral blood samples.

Previous studies have used multivariate statistical algorithms and artificial learning models to predict cancer prognosis and for grading different solid tumors ([@b15-ijo-49-03-0913],[@b23-ijo-49-03-0913]--[@b28-ijo-49-03-0913]). The majority of these studies reported varying degrees of sensitivity and specificity based on evaluation of different clinical parameters ([@b20-ijo-49-03-0913],[@b24-ijo-49-03-0913]).

Gene expression studies on hematological disease have been largely carried out by analysis of DNA or RNA microarrays. These genomics studies have indicated the potentials of large scale analysis of gene expression towards better understanding the molecular basis of leukemogenesis and that this information could potentially be useful in the classification of subtypes of hematological malignancies ([@b19-ijo-49-03-0913],[@b29-ijo-49-03-0913],[@b30-ijo-49-03-0913]). In a recent study of CLL samples, Alsagaby and colleagues used combined transcriptomics and proteomics analyses to unravel the heterogeneity of gene expression patterns as well attempting to identify proteins that are implicated in prognosis of chronic lymphocytic leukemia ([@b31-ijo-49-03-0913]). Recent studies have attempted to evaluate protein changes between imatinib sensitive and resistance samples ([@b32-ijo-49-03-0913]) as well as to better understand the molecular mechanism in therapy resistance at the level of bone marrow extracellular fluid in CML ([@b33-ijo-49-03-0913]).

Our initial analysis of 64 differentially expressed proteins of peripheral blood for prognostic monitoring of early CML treatment response at 6 months was encouraging and led us into extensive analysis of samples with sustained long-term MMR against patients that persistently could not achieve MMR.

Some of the identified proteins in the bone marrow of the 138 dataset for the prolonged and sustained MMR vs. persistent No-MMR were further evaluated for their functional characteristics and their hematological disease relevance using ingenuity pathway analysis (IPA). In the canonical pathway analysis of network signaling of identified proteins, only 48 of the 138 identified differentially expressed proteins were represented in the IPA database. The analysis of the identified proteins is composed of multiple networks of which, one is implicated in hematological disorders. The cellular localization, interconnections and functional annotation as well as the expression profile of some of these 48 identified molecules are as detailed in [Fig. 6A](#f6-ijo-49-03-0913){ref-type="fig"}. A review of some of these molecules showed that they mostly regulate among others: cell-to-cell signaling and interaction, hematological system development and function, aggregation of blood cells, coagulation, as well as quantity of granulocytes as indicated in [Fig. 6](#f6-ijo-49-03-0913){ref-type="fig"}. Among the identified proteins in this study is TYRO3 protein tyrosine kinase, a member of TAM family of receptor tyrosine kinases (RTKs) and known for their role as regulator of cellular proliferation, migration and survival processes, as well as maintenance of blood coagulation equilibrium ([@b34-ijo-49-03-0913]). We observed connection of TYRO 3 in AKT/P13K pathway; similar to that previously described ([@b34-ijo-49-03-0913]--[@b36-ijo-49-03-0913]).

The S100A8 is a calcium-binding protein of the S100 family and have been described to be associated with myeloid differentiation ([@b37-ijo-49-03-0913]). We observed a more than 9-fold differential expression of S100A8 and in the network connecting with RAS, TGFb, MAPK and MMP. The S-100 protein has been previously reported as a useful marker in juvenile chronic myeloid leukemia (JCML) as well as myeloid leukemia cutis (LC) ([@b38-ijo-49-03-0913],[@b39-ijo-49-03-0913]).

Overexpression of MYC has been associated with CML with poor response to imatinib ([@b40-ijo-49-03-0913],[@b41-ijo-49-03-0913]). We observed a more than 25-fold differential expression of MYC associated factor x in this study.

Altogether our findings indicate that rather than the use of a single marker, analyses of a panel of protein markers have the potential to provide better insight into complex biologic processes towards better prognostication of CML patients.

We recognize the limitation of this study as samples were prospectively collected and patients observed over the years for their treatment responses. One other issue with this study is the low number of patients enrolled in different clinical and molecular response groups; hence we have limited the analysis to evaluation of patients based on MMR and whether or not they are on IM or alternative treatment option (second generation TKI/others).

In conclusion, we have identified protein signatures capable of prediction of molecular response and choice of therapy for CML patients at 6 months and beyond using expression proteomics as objective stratification of CML patients for treatment options.

Although these results are very promising, we recognized that analysis of much larger materials of patients with similar treatments and responses will be necessary to validate if clustering analysis can be used as a routine prognostic tool for CML patients.

These proteins might be valuable once validated, to complement the currently existing parameters for reliable and objective prediction of disease progression, monitoring treatment response and clinical outcome of CML patients as a model of personalized medicine.

We thank Dr Abdelilah Aboussekhra for critical review, as well as Mr. Melvin Velasco, Mr. Parvez Siddiqui, Mr. Romeo Caracas and Ms. Tusneem Elhassan for technical assistant. We acknowledge the assistant and support of Mr. Faisal Al Otaibi and the logistics and purchasing department, RC, KFSH&RC. The present study was supported by the Research Center Administration, KFSH&RC, Riyadh, Saudi Arabia (RAC\# 2050 040).
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![Overview of our biomarker discovery proteomics approach. Bone marrow and peripheral blood samples were analyzed by 2-DE and LC/MS/MS. Identified proteins were subjected to statistical analysis and evaluated for early treatment response and prediction of individualized treatment options. Potential markers would be validated for clinical use.](IJO-49-03-0913-g00){#f1-ijo-49-03-0913}

![(A) Representative high resolution two-dimensional gel electrophoresis (2-DE) of proteins derived from CML bone marrow sample (Marked are differentially expressed protein spots between patients that achieved major molecular response from patients without major molecular response); P\<0.05 and at least 1.5-fold difference. (B) Principal component analysis (PCA) using datasets of 73 differentially expressed protein spots between groups of CML samples based on MMR (blue) and No-MMR (pink) at 6 months. The letters in grey in the background represents the protein spot numbers on the 2-DE gel of all the implicated protein spots used in the analysis.](IJO-49-03-0913-g01){#f2-ijo-49-03-0913}

![Unsupervised hierarchical cluster analysis of 64 identified differentially expressed proteins between patients that achieved MMR (blue) at 6 months from patients without MMR (No-MMR, red). The image was generated using J-Express Pro V 1.1 software program. (These 64 proteins used in generating this dendrogram plot are indicated by letter b in [Table II](#tII-ijo-49-03-0913){ref-type="table"}).](IJO-49-03-0913-g02){#f3-ijo-49-03-0913}

![(A) Principal component analysis (PCA) plot of CML peripheral blood samples using the expression dataset of 164 identified proteins that were significantly differentially expressed (\>1.5- to ∞-fold change; P\<0.05) between LT-MMR and P-No-MMR sample groups. The expression profiles of these proteins correctly predict patients with major molecular response (LT-MMR, blue) vs. no-major molecular response (P-No-MMR, purple) using principal component analysis. (B) Principal component analysis (PCA) plot of CML bone marrow samples using the expression dataset of 138 identified proteins that were significantly differentially expressed (\>1.5- to ∞-fold change; P\<0.05) between LT-MMR and P-No-MMR sample groups. The expression profiles of these proteins correctly predict patients with long-term major molecular response (LT-MMR, blue) vs. persistent no-major molecular response (P-No-MMR, purple) using principal component analysis. The letters in grey color in the background represents the accession numbers of all the implicated proteins in the analysis. \[Both images were generated using Progenesis QI for proteomics (Progenesis QIfp version 2.0.5387) (Nonlinear Dynamics/Waters)\].](IJO-49-03-0913-g03){#f4-ijo-49-03-0913}

![The same dataset from [Fig. 4B](#f4-ijo-49-03-0913){ref-type="fig"} (i.e. the expression of 138 identified bone marrow proteins that were significantly differentially expressed (\>1.5- to ∞-fold change; P\<0.05) between LT-MMR and P-No-MMR sample groups) separate all four sample groups including patients that stays on TKI after 1 year of imatinib Rx from patients ultimately requiring alternative treatment using principal component analysis. Long-term major molecular response (LT-MMR, blue), persistently no-major molecular response (P-No-MMR, purple, patients that stays on TKI after 1 year of imatinib Rx, green and patients ultimately requiring alternative treatment, red). The letters in grey color in the background represents the accession numbers of all the implicated proteins in the analysis. \[The image was generated using Progenesis QI for proteomics (Progenesis QIfp version 2.0.5387) (Nonlinear Dynamics/Waters)\]. Some of the identified proteins were implicated in hematological diseases as potential biomarkers using ingenuity pathway analysis as detailed in [Fig. 6](#f6-ijo-49-03-0913){ref-type="fig"}.](IJO-49-03-0913-g04){#f5-ijo-49-03-0913}

![(A) Pathway analysis of network signaling of some of the identified proteins as represented in the ingenuity pathway analysis database. The analysis of the identified proteins is composed of 2 hematological disease related networks with over 100 associated molecules that were merged into one as shown above. The connections and the expression profiles of some of the identified proteins are as indicated. Red indicates an upregulated protein, and pink color is indicative of downregulation. A direct connection is by solid line and broken lines indicate an indirect interaction between different molecules. Other molecules outside the identified in this study are in grey color. (B) The functional characteristics and disease relatedness of some of the identified proteins were mapped in Ingenuity database. The majority of these molecules are located mostly in the plasma membrane, cytoplasm and extracellular space, while only a few are located in the nucleus. Some these molecules functions as enzymes, transporters, transcription regulator, or G-protein coupled receptor. Others act as kinases, peptidase or growth factor. Furthermore, some of these molecules as represented in multiple sub-signaling networks mostly regulate among others: Cell-To-Cell Signaling and Interaction, Hematological System Development and Function. Other implicated functional annotations include, aggregation of blood cells, coagulation, quantity of aggregate cells as well as quantity of granulocytes. \[The network analysis was done and figure generated in ingenuity pathway analysis program (IPA v8.7)\].](IJO-49-03-0913-g05){#f6-ijo-49-03-0913}

![Unsupervised hierarchical cluster analysis of 54 identified differentially expressed proteins that are common in both bone marrow plasma (dataset of 138 proteins) and peripheral blood plasma (dataset of 164 proteins) of CML samples. The dendrogram shows correct prediction of patients with long-term major molecular response (LT-MMR, green), persistent no-major molecular response (P-No-MMR, blue), patients that stays on TKI after 1 year of imatinib Rx, purple and patients on alternative treatment outside TKI, red). The image was generated using J-Express Pro V 1.1 software program. (These 54 proteins used in generating this dendrogram plot are indicated with the letter a in [Table II](#tII-ijo-49-03-0913){ref-type="table"}).](IJO-49-03-0913-g06){#f7-ijo-49-03-0913}

![Western blots validation analysis abundance of 2 of the identified differentially expressed proteins. Each lane indicates the expression of 9 individual samples in each of the four sample groups representing long-term major molecular response to imatinib (LT-MMR), persistently no major molecular response (P-No-MMR), patients that stay on TKI after 1 year of imatinib treatment (On-TKI) and patients that ultimately required alternative treatment options, i.e. second generation TKI/others (Not-On-TKI). Albumin was used as internal standard for normalization. The histogram bars are the corresponding average group protein expressions of the two protein haptoglobin and hemoglobin using label-free LC/MS/MS expression analysis platform.](IJO-49-03-0913-g07){#f8-ijo-49-03-0913}

###### 

Clinical characteristics of analyzed samples.

                        TKI-fail   MMR at 6 months   MMR at 12 months   MMR at 18 months   MMR at 24 months                      
  ------- -------- ---- ---------- ----------------- ------------------ ------------------ ------------------ ---- ---- ---- --- ----
  CML1    Female   14   ✓                                               ✓                                     ✓         ✓        ✓
  CML2    Female   14   ✓                                               ✓                                     ✓         ✓        ✓
  CML3    Female   26              ✓                 ✓                                     ✓                                     
  CML4    Male     18              ✓                                    ✓                  ✓                       ✓             ✓
  CML5    Male     50   ✓                                               ✓                                     ✓         ✓        ✓
  CML6    Female   50   ✓                                               ✓                                     ✓         ✓        ✓
  CML7    Male     41              ✓                                    ✓                                     ✓         ✓        ✓
  CML8    Female   64              ✓                 ✓                                     ✓                       ✓         ✓   
  CML10   Male     27   ✓                                               ✓                  ✓                            ✓        ✓
  CML13   Male     44   ✓                                               ✓                                     ✓         ✓        ✓
  CML15   Male     21   ✓                                               ✓                                     ✓         ✓        ✓
  CML16   Male     44   ✓                                               ✓                                     ✓         ✓        ✓
  CML17   Female   18              ✓                 ✓                                     ✓                       ✓         ✓   
  CML18   Female   65   ✓                            ✓                                     ✓                       ✓         ✓   
  CML19   Male     26              ✓                 ✓                                     ✓                       ✓         ✓   
  CML21   Male     39              ✓                 ✓                                     ✓                            ✓        ✓
  CML22   Female   67   ✓                                               ✓                                     ✓         ✓        ✓
  CML23   Male     47   ✓                                               ✓                                     ✓         ✓        ✓
  CML24   Male     18              ✓                 ✓                                     ✓                       ✓         ✓   
  CML25   Male     40   ✓                                               ✓                                     ✓         ✓        ✓
  CML26   Female   30              ✓                 ✓                                                                           
  CML27   Female   36   ✓                            ✓                                                        ✓         ✓        ✓
  CML28   Female   37   ✓                                               ✓                                     ✓         ✓        ✓
  CML29   Female   33              ✓                 ✓                                     ✓                       ✓             ✓
  CML30   Female   44   ✓                                               ✓                                     ✓         ✓        ✓
  CML31   Female   48                                                                                                            
  CML32   Female   38              ✓                 ✓                                                                           
  CML33   Female   32              ✓                 ✓                                     ✓                                     
  CML34   Male     52              ✓                 ✓                                     ✓                       ✓         ✓   
  CML38   Male     37                                                                                                            
  CML40   Male     61              ✓                 ✓                                     ✓                       ✓             
  CML41   Male     47   ✓                                               ✓                                     ✓         ✓        ✓
  CML43   Female   51              ✓                 ✓                                     ✓                       ✓         ✓   
  CML44   Female   14   ✓                                               ✓                                     ✓         ✓        ✓
  CML45   Female   45   ✓                                               ✓                                     ✓         ✓        ✓
  CML46   Female   45   ✓                            ✓                                     ✓                            ✓        ✓
  CML47   Male     32              ✓                 ✓                                     ✓                       ✓         ✓   
  Total                 19         16                17                 18                 16                 17   11   20   8   22

###### 

The identified differentially expressed proteins in peripheral blood plasma (PBP) and bone marrow plasma (BMP) from CML patients with major molecular response (MMR), No-MMR, On-tyrosine kinase inhibitor (On-TKI) and NOT-on-TKI.

  A, The identified differentially expressed proteins in PBP of CML patients                                                                                                                                                                     
  -------------------------------------------------------------------------------------------------------------------- --------------------------------------- -------------- ----------------- ------------------------ ----------------------- -------------------------------------------------------------------------------------
  P50197                                                                                                               2                                       0.000534       2.41067           CML-PBP-TKI-Y            CML-PBP-MMR             2,5-dichloro-2,5-cyclohexadiene-1,4-diol dehydrogenase
  **P16281**                                                                                                           4                                       9.90E-08       2.92498           CML-PBP-TKI-N            CML-PBP-TKI-Y           **23 kDa protein**
  **P49313**                                                                                                           4                                       1.97E-07       9.09421           CML-PBP-TKI-Y            CML-PBP-No-MMR          **30 kDa ribonucleoprotein, chloroplast precursor**
  O86535                                                                                                               3                                       4.48E-12       22.9885           CML-PBP-TKI-N            CML-PBP-TKI-Y           3-isopropylmalate dehydratase small subunit
  P42352                                                                                                               1                                       2.83E-12       12.8902           CML-PBP-TKI-N            CML-PBP-MMR             50S ribosomal protein L9.
  O66190                                                                                                               3                                       0.001921       15.3266           CML-PBP-No-MMR           CML-PBP-TKI-N           60 kDa chaperonin (Protein Cpn60) (groEL protein)
  P50174                                                                                                               1                                       0.000148       2.33176           CML-PBP-TKI-Y            CML-PBP-MMR             Acetyl-CoA acetyltransferase
  P41341                                                                                                               5                                       1.37E-09       3.82215           CML-PBP-TKI-N            CML-PBP-No-MMR          Actin 11
  P53458                                                                                                               4                                       2.59E-10       25.5243           CML-PBP-TKI-Y            CML-PBP-No-MMR          Actin 5 (Fragment)
  P53506                                                                                                               4                                       1.85E-05       6.06449           CML-PBP-TKI-Y            CML-PBP-No-MMR          Actin, cytoplasmic type 8
  P53466[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 4                                       0.000178       4.16358           CML-PBP-TKI-N            CML-PBP-TKI-Y           Actin, cytoskeletal 2 (LPC2)
  P07326                                                                                                               1                                       1.50E-14       33782.8           CML-PBP-TKI-Y            CML-PBP-MMR             Allophycocyanin beta chain
  P72505                                                                                                               1                                       1.97E-11       50.0172           CML-PBP-TKI-Y            CML-PBP-TKI-N           Allophycocyanin beta chain
  P02763                                                                                                               9                                       8.94E-05       2.16961           CML-PBP-TKI-Y            CML-PBP-MMR             Alpha-1-acid glycoprotein 1 precursor (AGP 1)
  P19652                                                                                                               7                                       8.07E-10       3.8292            CML-PBP-TKI-Y            CML-PBP-MMR             Alpha-1-acid glycoprotein 2 precursor (AGP 2)
  **P01009**                                                                                                           35                                      7.33E-06       2.57662           CML-PBP-TKI-Y            CML-PBP-TKI-N           **Alpha-1-antitrypsin precursor**
  P04217[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 17                                      4.44E-11       2.21378           CML-PBP-TKI-Y            CML-PBP-MMR             Alpha-1B-glycoprotein
  P01023                                                                                                               71                                      4.34E-09       3.03669           CML-PBP-TKI-Y            CML-PBP-No-MMR          Alpha-2-macroglobulin precursor (Alpha-2-M)
  P39701                                                                                                               2                                       0.001857       17.1724           CML-PBP-MMR              CML-PBP-TKI-Y           Alpha-ribazole-5′-phosphate phosphatase
  P41361[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"},[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                  6                                       2.78E-07       2.68159           CML-PBP-TKI-N            CML-PBP-TKI-Y           Antithrombin-III (ATIII)
  P01008                                                                                                               15                                      1.56E-12       5.19919           CML-PBP-TKI-Y            CML-PBP-TKI-N           Antithrombin-III precursor (ATIII) (PRO0309)
  **P32262**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             6                                       2.65E-06       Infinity          CML-PBP-MMR              CML-PBP-TKI-Y           **Antithrombin-III precursor (ATIII)**
  P32261                                                                                                               8                                       7.40E-06       Infinity          CML-PBP-No-MMR           CML-PBP-TKI-Y           Antithrombin-III precursor (ATIII)
  P15497                                                                                                               4                                       8.88E-16       32.5405           CML-PBP-MMR              CML-PBP-TKI-Y           Apolipoprotein A-I precursor (Apo-AI)
  P18648                                                                                                               3                                       6.73E-08       2.76435           CML-PBP-MMR              CML-PBP-TKI-Y           Apolipoprotein A-I precursor (Apo-AI)
  **P02648**                                                                                                           12                                      7.81E-06       2.49354           CML-PBP-TKI-N            CML-PBP-TKI-Y           **Apolipoprotein A-I precursor (Apo-AI)**
  **P02652**                                                                                                           6                                       4.96E-10       3.48432           CML-PBP-TKI-Y            CML-PBP-No-MMR          **Apolipoprotein A-II precursor (Apo-AII) (ApoA-II)**
  **P06727**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             12                                      0.00063        2.06242           CML-PBP-TKI-Y            CML-PBP-TKI-N           **Apolipoprotein A-IV precursor (Apo-AIV)**
  P02655                                                                                                               2                                       3.46E-11       7.42195           CML-PBP-TKI-Y            CML-PBP-No-MMR          Apolipoprotein C-II precursor (Apo-CII)
  P02649                                                                                                               10                                      8.01E-08       3.13115           CML-PBP-TKI-Y            CML-PBP-No-MMR          Apolipoprotein E precursor (Apo-E)
  **P43773**                                                                                                           1                                       1.03E-08       3.21196           CML-PBP-TKI-N            CML-PBP-MMR             **ATP-dependent hsl protease ATP-binding subunit**
  **P01884**                                                                                                           1                                       2.13E-09       Infinity          CML-PBP-TKI-Y            CML-PBP-MMR             **Beta-2-microglobulin precursor**
  P31625                                                                                                               1                                       4.44E-16       29.2811           CML-PBP-TKI-Y            CML-PBP-MMR             Bifunctional protease/dUTPase \[Includes: Aspartic\]
  **Q08595**                                                                                                           2                                       5.42E-07       2.36202           CML-PBP-TKI-N            CML-PBP-No-MMR          **BR1 protein**
  **P06702**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             3                                       2.35E-12       5.10685           CML-PBP-No-MMR           CML-PBP-MMR             Calgranulin B (Migration inhibitory factor-related
  P07090                                                                                                               2                                       9.28E-09       4.35593           CML-PBP-TKI-Y            CML-PBP-MMR             Calretinin (CR)
  P00450                                                                                                               33                                      6.96E-10       2.07132           CML-PBP-TKI-Y            CML-PBP-TKI-N           Ceruloplasmin precursor (EC 1.16.3.1) (Ferroxidase)
  **P13635**                                                                                                           19                                      3.89E-07       2.06575           CML-PBP-TKI-Y            CML-PBP-No-MMR          **Ceruloplasmin precursor (EC 1.16.3.1) (Ferroxidase)**
  Q61147                                                                                                               19                                      6.29E-05       5.77271           CML-PBP-No-MMR           CML-PBP-TKI-N           Ceruloplasmin precursor (EC 1.16.3.1) (Ferroxidase)
  O34002                                                                                                               1                                       0.000137       68.1783           CML-PBP-MMR              CML-PBP-TKI-Y           Citrate synthase (EC 4.1.3.7)
  P23528                                                                                                               1                                       6.64E-09       17.4873           CML-PBP-No-MMR           CML-PBP-MMR             Cofilin, non-muscle isoform (18 kDa phosphoprotein)
  **Q03708**                                                                                                           2                                       2.25E-07       Infinity          CML-PBP-MMR              CML-PBP-TKI-N           **Colicin E7 immunity protein (ImmE7)**
  P00736                                                                                                               4                                       1.06E-11       3.2943            CML-PBP-TKI-Y            CML-PBP-No-MMR          Complement C1r component precursor
  P09871                                                                                                               4                                       2.38E-07       2.92284           CML-PBP-TKI-Y            CML-PBP-TKI-N           Complement C1s component precursor
  **P01027**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             22                                      1.58E-11       8.12844           CML-PBP-TKI-N            CML-PBP-TKI-Y           Complement C3 precursor (HSE-MSF)
  P01024                                                                                                               83                                      5.80E-10       2.95796           CML-PBP-TKI-Y            CML-PBP-TKI-N           Complement C3 precursor \[Contains: C3a anaphylatox\]
  P01030[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 20                                      0.001479       2.42252           CML-PBP-No-MMR           CML-PBP-TKI-N           Complement C4 precursor \[Contains: C4A anaphylatox\]
  **P04186**                                                                                                           7                                       0.000166       2.2386            CML-PBP-TKI-N            CML-PBP-MMR             **Complement factor B precursor (C3/C)**
  **P05156**                                                                                                           3                                       4.54E-07       3.80805           CML-PBP-TKI-Y            CML-PBP-No-MMR          **Complement factor I precursor (EC 3.4.21) (C3B/)**
  Q33439                                                                                                               1                                       6.13E-11       76.1488           CML-PBP-TKI-Y            CML-PBP-TKI-N           Cytochrome c oxidase polypeptide I
  P14532                                                                                                               1                                       8.42E-08       11.1984           CML-PBP-TKI-N            CML-PBP-TKI-Y           Cytochrome C551 peroxidase precursor
  **Q38732**                                                                                                           1                                       5.73E-08       16.099            CML-PBP-TKI-N            CML-PBP-TKI-Y           **DAG protein, chloroplast precursor**
  P57759                                                                                                               3                                       5.60E-13       5.45666           CML-PBP-TKI-N            CML-PBP-TKI-Y           Endoplasmic reticulum protein ERp29 precursor
  **P20710**                                                                                                           1                                       1.19E-08       24.9012           CML-PBP-TKI-N            CML-PBP-TKI-Y           **Excisionase**
  **Q45765**                                                                                                           1                                       0.000582       13.2686           CML-PBP-TKI-N            CML-PBP-No-MMR          **Ferric uptake regulation protein**
  P02671                                                                                                               23                                      0              5.53907           CML-PBP-TKI-Y            CML-PBP-TKI-N           Fibrinogen alpha/alpha-E chain precursor
  **P02675**                                                                                                           36                                      1.52E-09       2.8323            CML-PBP-TKI-Y            CML-PBP-TKI-N           **Fibrinogen beta chain precursor**
  P02679                                                                                                               26                                      6.02E-06       3.07718           CML-PBP-TKI-Y            CML-PBP-TKI-N           Fibrinogen gamma chain precursor
  **P11276**                                                                                                           11                                      0.000201       2.27101           CML-PBP-No-MMR           CML-PBP-TKI-N           **Fibronectin precursor (FN) (Fragments)**
  P08041                                                                                                               1                                       4.74E-05       4.36822           CML-PBP-MMR              CML-PBP-TKI-Y           Gas vesicle protein C
  P47805                                                                                                               2                                       0.005106       6.89488           CML-PBP-TKI-Y            CML-PBP-MMR             Gastrulation specific protein G12
  P13020                                                                                                               3                                       2.96E-06       2.44545           CML-PBP-TKI-Y            CML-PBP-MMR             Gelsolin (Actin-depolymerizing factor)
  P06396                                                                                                               3                                       0.000102       4.00281           CML-PBP-TKI-Y            CML-PBP-TKI-N           Gelsolin precursor, plasma (Actin-depolymerizing)
  **P06228**                                                                                                           2                                       5.86E-07       2.30924           CML-PBP-TKI-Y            CML-PBP-TKI-N           **Gene 27 protein**
  P15751                                                                                                               1                                       1.74E-07       2.52369           CML-PBP-TKI-Y            CML-PBP-MMR             General secretion pathway protein L
  P23722                                                                                                               4                                       0.004817       3.55572           CML-PBP-MMR              CML-PBP-TKI-N           Glyceraldehyde 3-phosphate dehydrogenase
  **P55042**                                                                                                           2                                       1.22E-08       4.00025           CML-PBP-TKI-Y            CML-PBP-TKI-N           **GTP-binding protein RAD (RAS associated)**
  P00739                                                                                                               13                                      3.99E-11       5.55201           CML-PBP-TKI-Y            CML-PBP-TKI-N           Haptoglobin-related protein precursor
  **P91953**                                                                                                           1                                       1.37E-07       4.42879           CML-PBP-TKI-Y            CML-PBP-No-MMR          **Hatching enzyme precursor (HE) (HEZ)**
  P01922                                                                                                               6                                       6.01E-14       10.9884           CML-PBP-TKI-Y            CML-PBP-MMR             Hemoglobin α chain
  P07414                                                                                                               2                                       0.001548       22.3314           CML-PBP-No-MMR           CML-PBP-TKI-N           Hemoglobin α chain
  **P19002**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             2                                       2.15E-05       2.87378           CML-PBP-No-MMR           CML-PBP-MMR             **Hemoglobin** α**-1,** α**-2, and** α**-3 chains**
  P02054                                                                                                               4                                       8.10E-15       54.1252           CML-PBP-TKI-Y            CML-PBP-MMR             Hemoglobin β chain
  P14391                                                                                                               5                                       4.48E-11       5.10044           CML-PBP-TKI-N            CML-PBP-No-MMR          Hemoglobin β chain
  P18985                                                                                                               8                                       1.04E-09       2.8812            CML-PBP-TKI-Y            CML-PBP-No-MMR          Hemoglobin β chain
  P02134                                                                                                               2                                       2.66E-09       19.544            CML-PBP-MMR              CML-PBP-TKI-Y           Hemoglobin β chain
  P18984                                                                                                               5                                       4.21E-09       3.66515           CML-PBP-TKI-Y            CML-PBP-MMR             Hemoglobin β chain
  P02049                                                                                                               5                                       3.19E-05       976.807           CML-PBP-TKI-Y            CML-PBP-No-MMR          Hemoglobin β chain
  P11758                                                                                                               6                                       0.002277       13.0218           CML-PBP-MMR              CML-PBP-TKI-N           Hemoglobin β chain
  P02094[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 2                                       0.004366       7.02752           CML-PBP-MMR              CML-PBP-TKI-N           Hemoglobin β-major chain
  Q28220                                                                                                               4                                       0.000235       30.7953           CML-PBP-TKI-N            CML-PBP-TKI-Y           Hemoglobin ɛ chain
  P05546                                                                                                               13                                      0.005774       2.11422           CML-PBP-TKI-Y            CML-PBP-TKI-N           Heparin cofactor II precursor (HC-II)
  P33433                                                                                                               5                                       0.000577       3.03464           CML-PBP-MMR              CML-PBP-TKI-N           Histidine-rich glycoprotein (Histidine-proline rich)
  Q28640                                                                                                               5                                       0.001028       6.73632           CML-PBP-MMR              CML-PBP-TKI-N           Histidine-rich glycoprotein precursor
  P11457                                                                                                               1                                       2.09E-10       43.477            CML-PBP-TKI-N            CML-PBP-TKI-Y           Histone-like protein HLP-1 precursor (DNA-binding)
  P09631[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       8.27E-14       6.74686           CML-PBP-MMR              CML-PBP-TKI-Y           Homeobox protein Hox-A9 (Hox-1.7)
  **Q10521**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             1                                       2.13E-05       3.30175           CML-PBP-TKI-Y            CML-PBP-TKI-N           **Hypothetical 16.9 kDa protein Rv2239c**
  P37506[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       8.12E-10       3.91542           CML-PBP-TKI-Y            CML-PBP-MMR             Hypothetical 20.4 kDa protein in COTF-T**ETB**
  **Q10616**                                                                                                           **1**                                   **1.93E-06**   **2.87092**       **CML-PBP-TKI-N**        **CML-PBP-TKI-Y**       Hypothetical 56.0 kDa protein Rv1290c
  P07083                                                                                                               1                                       0.000415       11.8324           CML-PBP-No-MMR           CML-PBP-TKI-N           Hypothetical 9.8 kDa protein in Gp55-nrdG intergenic region
  Q9KD45                                                                                                               2                                       1.21E-10       3.97407           CML-PBP-MMR              CML-PBP-TKI-Y           Hypothetical protein BH1374
  P47679                                                                                                               2                                       0.000507       4.0852            CML-PBP-TKI-Y            CML-PBP-TKI-N           Hypothetical protein MG441
  P42962[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 2                                       0.000554       9.91114           CML-PBP-TKI-Y            CML-PBP-TKI-N           Hypothetical protein ycsE
  P54462                                                                                                               2                                       2.28E-13       60.8113           CML-PBP-MMR              CML-PBP-TKI-Y           Hypothetical protein yqeV
  **P01876**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             14                                      1.04E-12       4.48826           CML-PBP-TKI-N            CML-PBP-MMR             **Ig alpha-1 chain C region**
  **P01862**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             2                                       0.001527       Infinity          CML-PBP-No-MMR           CML-PBP-TKI-N           **Ig gamma-2 chain C region**
  P01860                                                                                                               11                                      0.000542       4.16369           CML-PBP-TKI-Y            CML-PBP-No-MMR          Ig gamma-3 chain C region (Heavy chain)
  P01861                                                                                                               14                                      3.90E-09       2.35422           CML-PBP-TKI-Y            CML-PBP-No-MMR          Ig gamma-4 chain C region
  **P19181**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             4                                       0.005572       2.28883           CML-PBP-MMR              CML-PBP-TKI-N           **Ig heavy chain V region 5A precursor**
  **P01765**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             2                                       4.91E-09       5.63765           CML-PBP-TKI-N            CML-PBP-TKI-Y           **Ig heavy chain V-III region TIL**
  **P01620**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             5                                       0.000589       11.6515           CML-PBP-No-MMR           CML-PBP-TKI-N           **Ig kappa chain V-III region SIE**
  P01842                                                                                                               6                                       0.000394       2.20304           CML-PBP-TKI-Y            CML-PBP-TKI-N           Ig lambda chain C regions
  P01714                                                                                                               2                                       5.10E-12       3.83063           CML-PBP-No-MMR           CML-PBP-TKI-Y           Ig lambda chain V-III region SH
  P04220                                                                                                               12                                      7.49E-06       3.79369           CML-PBP-TKI-N            CML-PBP-TKI-Y           Ig MU heavy chain disease protein (BOT)
  P01591                                                                                                               5                                       0.000549       5.43077           CML-PBP-No-MMR           CML-PBP-TKI-N           Immunoglobulin J chain
  P15814                                                                                                               2                                       9.08E-06       5.19282           CML-PBP-MMR              CML-PBP-TKI-Y           Immunoglobulin lambda-like polypeptide 1
  P36228                                                                                                               1                                       0.000179       3.92057           CML-PBP-MMR              CML-PBP-TKI-Y           Infection structure-specific protein 56
  P56289                                                                                                               3                                       3.29E-07       2.32089           CML-PBP-TKI-N            CML-PBP-No-MMR          Initiation factor EIF-5A-1
  P01314                                                                                                               1                                       2.90E-09       5.68794           CML-PBP-TKI-N            CML-PBP-TKI-Y           Insulin
  O02833                                                                                                               6                                       2.32E-09       183.422           CML-PBP-MMR              CML-PBP-TKI-Y           Insulin-like growth factor binding protein complex
  P19827[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 13                                      2.04E-07       2.19294           CML-PBP-TKI-N            CML-PBP-TKI-Y           Inter-alpha-trypsin inhibitor heavy chain H1 precursor
  **P56651**                                                                                                           1                                       5.41E-11       18.9887           CML-PBP-MMR              CML-PBP-TKI-Y           **Inter-alpha-trypsin inhibitor heavy chain H2**
  **P19823**                                                                                                           17                                      0.001377       2.02663           CML-PBP-TKI-Y            CML-PBP-TKI-N           **Inter-alpha-trypsin inhibitor heavy chain H2**
  P02750                                                                                                               7                                       1.91E-12       2.51124           CML-PBP-TKI-N            CML-PBP-MMR             Leucine-rich alpha-2-glycoprotein (LRG)
  P06267                                                                                                               2                                       1.32E-12       4.06168           CML-PBP-TKI-N            CML-PBP-No-MMR          Light-independent protochlorophyllide reductase
  P18428                                                                                                               2                                       7.86E-08       2.56066           CML-PBP-TKI-Y            CML-PBP-MMR             Lipopolysaccharide-binding protein precursor (LBP)
  P13796[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 4                                       9.06E-13       7.72276           CML-PBP-No-MMR           CML-PBP-TKI-Y           L-plastin (Lymphocyte cytosolic protein 1) (LCP-1)
  **P28717**                                                                                                           1                                       2.95E-07       4.88405           CML-PBP-TKI-Y            CML-PBP-TKI-N           **Mating pheromone 3 precursor**
  **Q9RV62**                                                                                                           1                                       8.32E-07       2.27719           CML-PBP-TKI-N            CML-PBP-MMR             **NADH pyrophosphatase (EC 3.6.1.-)**
  P41211                                                                                                               1                                       2.57E-06       2.48053           CML-PBP-MMR              CML-PBP-TKI-Y           Neuron specific calcium-binding protein
  **P70563**                                                                                                           1                                       0.000537       13.799            CML-PBP-No-MMR           CML-PBP-TKI-N           **Nucleoside diphosphate-linked moiety X motif 6**
  **P14287**                                                                                                           1                                       5.51E-05       142.537           CML-PBP-MMRs             CML-PBP-TKI-N           **Osteopontin precursor (Bone sialoprotein 1)**
  P97085                                                                                                               2                                       2.31E-06       2.01262           CML-PBP-TKI-Y            CML-PBP-MMR             Outer membrane protein U precursor (Porin ompU)
  P31544                                                                                                               2                                       0.000651       49.286            CML-PBP-MMR              CML-PBP-TKI-Y           PhoH protein (Phosphate starvation-inducible protein
  **P57093**                                                                                                           1                                       4.74E-10       5.0011            CML-PBP-No-MMR           CML-PBP-TKI-Y           **Phytanoyl-CoA dioxygenase, peroxisomal**
  **P03952**                                                                                                           2                                       5.36E-10       3.76097           CML-PBP-TKI-Y            CML-PBP-No-MMR          **Plasma kallikrein precursor**
  P02753[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 4                                       5.90E-13       3.91711           CML-PBP-TKI-Y            CML-PBP-No-MMR          Plasma retinol-binding protein precursor (PRBP)
  P21922                                                                                                               1                                       0.000235       36.2475           CML-PBP-TKI-Y            CML-PBP-No-MMR          Precorrin-4 C11-methyltransferase
  Q06253                                                                                                               2                                       1.39E-09       4.17508           CML-PBP-MMR              CML-PBP-TKI-Y           Prevent host death protein
  P07737[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 3                                       3.18E-14       14.753            CML-PBP-TKI-Y            CML-PBP-MMR             Profilin I
  **P26604**                                                                                                           1                                       0.001614       Infinity          CML-PBP-No-MMR           CML-PBP-TKI-Y           **Protein hdeA precursor (10K-S protein)**
  Q9SM41                                                                                                               1                                       5.77E-08       6.67068           CML-PBP-TKI-N            CML-PBP-TKI-Y           Protein translation factor SUI1 homolog.
  P00734                                                                                                               15                                      0.000479       3.44209           CML-PBP-TKI-Y            CML-PBP-TKI-N           Prothrombin precursor (EC 3.4.21.5)
  Q55794                                                                                                               2                                       2.35E-13       8.13328           CML-PBP-TKI-N            CML-PBP-MMR             Putative arsenical pump-driving ATPase
  Q15418                                                                                                               4                                       0.004805       6.05567           CML-PBP-TKI-N            CML-PBP-TKI-Y           Ribosomal protein S6 kinase alpha 1
  P00580                                                                                                               3                                       2.27E-09       4.02263           CML-PBP-TKI-N            CML-PBP-TKI-Y           RNA polymerase sigma-32 factor (Heat shock regulator)
  P14072                                                                                                               1                                       0.000233       168.597           CML-PBP-No-MMR           CML-PBP-TKI-N           Rubredoxin (Rd)
  P58402                                                                                                               2                                       9.27E-06       9.67406           CML-PBP-TKI-N            CML-PBP-TKI-Y           Sensor protein evgS precursor
  Q9ZK14                                                                                                               2                                       6.65E-12       18.9567           CML-PBP-TKI-N            CML-PBP-TKI-Y           Serine acetyltransferase (SAT)
  **P02787**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             53                                      2.49E-05       2.63861           CML-PBP-TKI-Y            CML-PBP-TKI-N           **Serotransferrin precursor (Siderophilin)**
  P49064[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 4                                       5.43E-05       Infinity          CML-PBP-TKI-Y            CML-PBP-MMR             Serum albumin precursor (Allergen Fel d 2)
  Q28522                                                                                                               43                                      5.22E-11       5.61756           CML-PBP-TKI-Y            CML-PBP-No-MMR          Serum albumin precursor (Fragment)
  P02768                                                                                                               120                                     1.15E-09       2.87802           CML-PBP-TKI-Y            CML-PBP-No-MMR          Serum albumin precursor
  P02743                                                                                                               1                                       1.17E-12       6.80911           CML-PBP-TKI-Y            CML-PBP-TKI-N           Serum amyloid P-component precursor (SAP)
  P27169                                                                                                               5                                       2.21E-05       2.43474           CML-PBP-TKI-Y            CML-PBP-MMR             Serum paraoxonase/arylesterase 1
  P04278                                                                                                               2                                       8.55E-09       4.0875            CML-PBP-TKI-Y            CML-PBP-No-MMR          Sex hormone-binding globulin precursor (SHBG)
  P95340[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       3.77E-15       16.6343           CML-PBP-TKI-Y            CML-PBP-No-MMR          Shikimate 5-dehydrogenase
  P57675                                                                                                               1                                       1.56E-07       24.6905           CML-PBP-TKI-Y            CML-PBP-MMR             Stanniocalcin 2 (STC-2) (Fragments)
  Q9R0K8                                                                                                               2                                       2.68E-10       6.96573           CML-PBP-TKI-Y            CML-PBP-MMR             Stanniocalcin 2 precursor (STC-2)
  P41691                                                                                                               3                                       4.82E-11       19.1566           CML-PBP-TKI-Y            CML-PBP-TKI-N           Superfast myosin regulatory light chain 2 (MYLC2)
  P03729                                                                                                               1                                       2.18E-12       11.1468           CML-PBP-TKI-N            CML-PBP-TKI-Y           Tail assembly protein K
  **P43691**                                                                                                           3                                       9.61E-11       3.55237           CML-PBP-No-MMR           CML-PBP-TKI-Y           **Transcription factor GATA-4(GATA binding factor-4)**
  O22347                                                                                                               1                                       0.002132       12.1326           CML-PBP-MMR              CML-PBP-TKI-N           Tubulin alpha-1 chain (Alpha-1 tubulin)
  P12459                                                                                                               1                                       8.40E-14       9.68647           CML-PBP-TKI-N            CML-PBP-No-MMR          Tubulin beta-1 chai
  **P02774**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             17                                      2.45E-07       2.6983            CML-PBP-TKI-Y            CML-PBP-No-MMR          **Vitamin D-binding protein precursor (DBP) (Group-s)**
  **P04004**                                                                                                           9                                       6.06E-09       2.12057           CML-PBP-TKI-Y            CML-PBP-MMR             **Vitronectin precursor (Serum spreading factor)**
                                                                                                                                                                                                                                                 
  B, The identified differentially expressed proteins in BMP of CML patients with MMR, No-MMR, On-TKI and NOT-on-TKI                                                                                                                             
                                                                                                                                                                                                                                                 
  Accession                                                                                                            Peptide count used for quantification   Anova (p)      Max fold change   Highest mean condition   Lowest mean condition   Description
                                                                                                                                                                                                                                                 
  Q9ZEY8                                                                                                               2                                       0.00866        1.5676            CMR-N                    TKI-N                   2-isopropylmalate synthase (EC 4.1.3.12)
  P49313[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"},[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                  1                                       0.00086        2.8992            TKI-N                    CMR-Y                   30 kDa ribonucleoprotein, chloroplast precursor
  P02578[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00023        2.4784            TKI-N                    CMR-Y                   Actin 1
  **Q03341**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **1**                                   **0.00033**    **19.7447**       **CMR-N**                **TKI-Y**               **Actin 2**
  P02580[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 2                                       0.00001        16.5471           CMR-Y                    CMR-N                   Actin 3
  P07829                                                                                                               1                                       0.01832        3.2349            CMR-Y                    TKI-N                   Actin 3-SUB1
  P93584                                                                                                               1                                       0.01376        1.5206            CMR-N                    CMR-Y                   Actin 82 (Fragment)
  P53460                                                                                                               1                                       0.00928        8.5512            TKI-N                    CMR-N                   Actin, muscle 1A
  P50138[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00431        88.6922           CMR-Y                    TKI-Y                   Actin
  Q9P4D1                                                                                                               1                                       0.01099        3.7590            CMR-Y                    TKI-Y                   Actin
  **P43652**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **13**                                  **0.00003**    **2.0878**        **CMR-Y**                **TKI-N**               **Afamin precursor (Alpha-albumin) (Alpha-Alb)**
  P19652[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 6                                       0.00163        1.5175            CMR-Y                    TKI-N                   Alpha-1-acid glycoprotein 2 precursor (AGP 2)
  P01010[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00421        2.2484            CMR-Y                    CMR-N                   Alpha-1-antitrypsin precursor (Alpha-1 protease inhibitor)
  **P01009**                                                                                                           **27**                                  **0.02049**    **1.7589**        **CMR-Y**                **TKI-N**               **Alpha-1-antitrypsin precursor (Alpha-1 protease inhibitor)**
  **P08697**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **7**                                   **0.00231**    **2.7616**        **CMR-Y**                **TKI-N**               **Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor)**
  Q9N2D0                                                                                                               1                                       0.03147        4.9779            CMR-Y                    TKI-N                   Alpha-2-HS-glycoprotein precursor (Fetuin-A)
  P01023[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 67                                      0.00130        1.5666            CMR-Y                    TKI-N                   Alpha-2-macroglobulin precursor (Alpha-2-M)
  P01019                                                                                                               11                                      0.02295        1.4615            CMR-Y                    CMR-N                   Angiotensinogen precursor \[Contains: Angiotensin I
  P00896[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00001        5.0581            CMR-N                    TKI-N                   Anthranilate synthase component I (EC 4.1.3.27)
  P01008[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 9                                       0.00320        1.4376            CMR-Y                    TKI-Y                   Antithrombin-III precursor (ATIII) (PRO0309)
  P32261[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 2                                       0.00084        5.0712            TKI-N                    CMR-N                   Antithrombin-III precursor (ATIII)
  P09809                                                                                                               2                                       0.02421        1.5680            TKI-N                    CMR-Y                   Apolipoprotein A-I precursor (Apo-AI)
  **P15497**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             **2**                                   **0.03898**    **4.7003**        **CMR-Y**                **CMR-N**               **Apolipoprotein A-I precursor (Apo-AI)**
  P06727                                                                                                               14                                      0.01399        2.0475            CMR-Y                    TKI-Y                   Apolipoprotein A-IV precursor (Apo-AIV)
  P02655[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"},[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                  2                                       0.00001        2.0801            CMR-Y                    TKI-N                   Apolipoprotein C-II precursor (Apo-CII)
  P41697                                                                                                               1                                       0.00423        1.9243            TKI-Y                    CMR-N                   Bud site selection protein BUD6 (Actin interacting protein)
  P05109                                                                                                               2                                       0.04617        9.0518            CMR-Y                    TKI-N                   Calgranulin A (Migration inhibitory factor-related protein)
  P25854                                                                                                               2                                       0.01368        1.5390            TKI-Y                    CMR-N                   Calmodulin-1 (Fragment)
  **Q9NZT1**                                                                                                           **1**                                   **0.00088**    **1.9462**        **CMR-N**                **TKI-Y**               **Calmodulin-like skin protein**
  Q00371[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00002        23.1103           TKI-N                    CMR-N                   CAP22 protein
  P00915[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 6                                       0.00072        5.4236            CMR-N                    TKI-N                   Carbonic anhydrase I (EC 4.2.1.1) (Carbonate dehydrase)
  P25773[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00000        6.6740            CMR-Y                    CMR-N                   Cathepsin L (EC 3.4.22.15) (Progesterone-dependent)
  **P00450**                                                                                                           **20**                                  **0.00727**    **1.5284**        **CMR-Y**                **CMR-N**               **Ceruloplasmin precursor (EC 1.16.3.1) (Ferroxidase)**
  P13635                                                                                                               6                                       0.02286        1.5201            CMR-Y                    TKI-N                   Ceruloplasmin precursor (EC 1.16.3.1) (Ferroxidase)
  Q61147                                                                                                               5                                       0.03054        2.4399            TKI-N                    TKI-Y                   Ceruloplasmin precursor (EC 1.16.3.1) (Ferroxidase)
  **P10909**                                                                                                           **6**                                   **0.00012**    **1.5866**        **CMR-Y**                **CMR-N**               **Clusterin precursor (Complement-associated protein)**
  P25958                                                                                                               3                                       0.00747        1.9061            TKI-Y                    TKI-N                   ComG operon protein 6
  **P02747**                                                                                                           **2**                                   **0.04052**    **28.8755**       **CMR-Y**                **TKI-Y**               **Complement C1q subcomponent, C chain precursor**
  **P01026**                                                                                                           **10**                                  **0.00001**    **1.8285**        **TKI-N**                **CMR-Y**               **Complement C3 precursor \[Contains: C3A anaphylatox\]**
  P12387                                                                                                               7                                       0.00010        1.8101            CMR-N                    CMR-Y                   Complement C3 precursor \[Contains: C3A anaphylatox\]
  **P01024**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             **68**                                  **0.00088**    **1.6430**        **CMR-Y**                **TKI-N**               **Complement C3 precursor \[Contains: C3a anaphylatox\]**
  P01028[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 42                                      0.00020        2.0579            CMR-Y                    TKI-Y                   Complement C4 precursor \[Contains: C4A anaphylatox\]
  **P10643**                                                                                                           **3**                                   **0.04712**    **1.4974**        **CMR-Y**                **CMR-N**               **Complement component C7 precursor**
  P02748[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 7                                       0.00131        2.5543            CMR-Y                    TKI-N                   Complement component C9 precursor
  **P08603**                                                                                                           **30**                                  **0.00365**    **1.4060**        **CMR-Y**                **TKI-N**               **Complement factor H precursor (H factor 1)**
  **P48416**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **3**                                   **0.00000**    **3.5184**        **TKI-N**                **CMR-Y**               **Cytochrome P450 10 (EC 1.14.-.-) (CYPX)**
  Q92I25[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00007        2.6454            TKI-Y                    CMR-N                   Dihydrodipicolinate synthase (EC 4.2.1.52) (DHDPS)
  P31073[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00010        2.2735            TKI-N                    CMR-N                   Dihydrofolate reductase (EC 1.5.1.3)
  P20861[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00000        16.7020           TKI-N                    CMR-Y                   Fan G protein precursor
  **P02671**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"},[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}              21                                      0.00003        2.2257            CMR-Y                    TKI-Y                   Fibrinogen alpha/alpha-E chain precursor
  P02675[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"},[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                  24                                      0.00010        2.4767            CMR-Y                    CMR-N                   Fibrinogen beta chain precursor \[Contains: Fibrinogen\]
  **Q02020**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **2**                                   **0.00461**    **2.5361**        **CMR-Y**                **CMR-N**               **Fibrinogen beta chain precursor \[Contains: Fibrinogen\]**
  **P14480**                                                                                                           **7**                                   **0.00542**    **2.0499**        **CMR-N**                **CMR-Y**               **Fibrinogen beta chain precursor \[Contains: Fibrinogen\]**
  P02679[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"},[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                  13                                      0.00110        2.1792            CMR-Y                    CMR-N                   Fibrinogen gamma chain precursor
  Q92T27                                                                                                               2                                       0.00030        1.5959            TKI-N                    CMR-N                   Glucokinase (EC 2.7.1.2) (Glucose kinase)
  **Q92J74**                                                                                                           **1**                                   **0.00712**    **2.6314**        **CMR-Y**                **CMR-N**               **Glutamyl-tRNA(Gln) amidotransferase subunit C**
  Q60759                                                                                                               4                                       0.00301        1.8431            TKI-N                    CMR-Y                   Glutaryl-CoA dehydrogenase, mitochondrial precursor
  **P23722**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             **3**                                   **0.00380**    **1.5602**        **TKI-N**                **CMR-Y**               **Glyceraldehyde 3-phosphate dehydrogenase**
  **Q9ZKP0**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"},[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}              **2**                                   **0.00292**    **2.4902**        **CMR-Y**                **TKI-N**               **Glycerol-3-phosphate dehydrogenase \[NAD(P)+\]**
  P50150                                                                                                               1                                       0.03327        5.9505            TKI-N                    CMR-Y                   Guanine nucleotide-binding protein G(I)/G(S)/G(O)
  **P07736**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **1**                                   **0.00189**    **2.7741**        **TKI-N**                **CMR-Y**               **Guanyl-specific ribonuclease U1 (EC 3.1.27.3) (Rna)**
  **P50417**                                                                                                           **1**                                   **0.00764**    **5.7455**        **CMR-Y**                **TKI-N**               **Haptoglobin precursor**
  P00738                                                                                                               4                                       0.04834        2.6291            CMR-Y                    TKI-Y                   Haptoglobin-2 precursor
  P07414                                                                                                               2                                       0.00753        8.8724            CMR-N                    TKI-N                   Hemoglobin alpha chain
  P01932                                                                                                               1                                       0.04336        Infinity          CMR-Y                    TKI-Y                   Hemoglobin alpha chain
  **P01948**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **1**                                   **0.00432**    **2.0401**        **TKI-Y**                **CMR-Y**               **Hemoglobin alpha-1 and alpha-2 chains**
  Q9XSN3                                                                                                               1                                       0.00834        1.3880            CMR-Y                    TKI-N                   Hemoglobin alpha-1 chain
  P19002[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 2                                       0.00000        3.9434            CMR-N                    CMR-Y                   Hemoglobin alpha-1, alpha-2, and alpha-3 chains
  P02037[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00166        5.3495            CMR-N                    TKI-Y                   Hemoglobin beta chain
  **P11758**                                                                                                           **2**                                   **0.03762**    **3.2576**        **CMR-Y**                **TKI-Y**               **Hemoglobin beta chain**
  P02027                                                                                                               1                                       0.04456        16.1529           CMR-N                    CMR-Y                   Hemoglobin beta chain
  P02064                                                                                                               1                                       0.02202        2.3093            TKI-N                    CMR-N                   Hemoglobin beta-1 chain (Major)
  P02074[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00000        4.1199            CMR-N                    CMR-Y                   Hemoglobin beta-III chain
  P19886[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 2                                       0.00008        2.0278            CMR-N                    CMR-Y                   Hemoglobin delta chain
  **P20058**                                                                                                           **2**                                   **0.03619**    **1.8809**        **TKI-N**                **CMR-N**               **Hemopexin precursor**
  P45965                                                                                                               1                                       0.04029        13.7398           CMR-Y                    CMR-N                   Hypothetical 19.4 kDa protein T09A5.5 in chromosome
  Q05107                                                                                                               1                                       0.02505        2.0311            CMR-Y                    CMR-N                   Hypothetical 23.6 kDa protein
  O34717                                                                                                               2                                       0.01355        1.4268            TKI-Y                    CMR-Y                   Hypothetical oxidoreductase ykuF (EC 1)
  **P44030**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **1**                                   **0.00000**    **4.4405**        **TKI-Y**                **CMR-Y**               **Hypothetical protein HI0659**
  **P42968**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **1**                                   **0.00003**    **4.3060**        **TKI-N**                **CMR-N**               **Hypothetical transcriptional regulator ycsO**
  P01876[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"},[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                  1                                       0.00013        3.1121            CMR-Y                    CMR-N                   Ig alpha-1 chain C region
  **P01859**                                                                                                           **8**                                   **0.00015**    **1.8808**        **TKI-Y**                **TKI-N**               **Ig gamma-2 chain C region**
  P01860[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 3                                       0.00018        1.4555            TKI-Y                    TKI-N                   Ig gamma-3 chain C region (Heavy chain disease protein)
  P01861[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 5                                       0.02495        1.4049            CMR-Y                    TKI-N                   Ig gamma-4 chain C region
  P01779                                                                                                               2                                       0.02052        2.4688            CMR-Y                    CMR-N                   Ig heavy chain V-III region TUR
  P01617                                                                                                               1                                       0.00016        1.9790            CMR-Y                    TKI-N                   Ig kappa chain V-II region TEW
  **P01625**                                                                                                           **3**                                   **0.01464**    **1.8173**        **CMR-Y**                **CMR-N**               **Ig kappa chain V-IV region Len**
  **P01842**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             **5**                                   **0.00763**    **1.4632**        **CMR-Y**                **CMR-N**               **Ig lambda chain C regions**
  **P01591**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                             **5**                                   **0.03430**    **2.1773**        **CMR-Y**                **TKI-Y**               **Immunoglobulin J chain**
  **P01335**                                                                                                           **1**                                   **0.00514**    **2.4827**        **TKI-N**                **CMR-Y**               **Insulin precursor**
  O02668                                                                                                               1                                       0.01041        13.1392           CMR-Y                    TKI-Y                   Inter-alpha-trypsin inhibitor heavy chain H2 precursor
  P97279                                                                                                               2                                       0.03423        2.0472            TKI-Y                    TKI-N                   Inter-alpha-trypsin inhibitor heavy chain H2 precursor
  Q42891[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00002        2.2505            TKI-N                    CMR-N                   Lactoylglutathione lyase (EC 4.4.1.5) (Methylglyoxal)
  P02750[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 9                                       0.01798        1.3841            TKI-Y                    CMR-N                   Leucine-rich alpha-2-glycoprotein (LRG)
  **P06267**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"},[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}              **1**                                   **0.00005**    **3.9296**        **CMR-N**                **TKI-N**               **Light-independent protochlorophyllide reductase iron-sulfur ATP-binding protein**
  Q61233                                                                                                               2                                       0.01594        3.5492            CMR-Y                    TKI-Y                   L-plastin (Lymphocyte cytosolic protein 1) (LCP-1)
  P52162                                                                                                               1                                       0.01027        25.2703           CMR-Y                    TKI-N                   MAX protein
  P48310[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00024        2.4866            CMR-Y                    TKI-N                   Minor capsid protein VI precursor
  **O03698**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **1**                                   **0.00041**    **2.9113**        **CMR-N**                **CMR-Y**               **NADH-ubiquinone oxidoreductase chain 4 (EC 1.6.5.3)**
  Q43875                                                                                                               1                                       0.01342        4.0047            CMR-Y                    CMR-N                   Nonspecific lipid-transfer protein 4.2 precursor
  P23051                                                                                                               1                                       0.00002        3.3474            TKI-Y                    TKI-N                   Nucleocapsid protein
  P39115[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00000        3.4012            CMR-N                    CMR-Y                   Nucleotide binding protein ExpZ
  P32119[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 3                                       0.00000        4.3238            CMR-N                    CMR-Y                   Peroxiredoxin 2 (Thioredoxin peroxidase 1)
  **Q42858**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **1**                                   **0.00007**    **4.2693**        **CMR-N**                **TKI-N**               **Phenylalanine ammonia-lyase (EC 4.3.1.5)**
  O07125[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00099        2.7853            CMR-N                    TKI-N                   Phosphocarrier protein HPr (ptsH)
  P09411                                                                                                               1                                       0.01886        1.5949            TKI-Y                    TKI-N                   Phosphoglycerate kinase 1 (EC 2.7.2.3)
  **Q9KDM4**                                                                                                           **2**                                   **0.00513**    **1.6582**        **TKI-N**                **CMR-N**               **Phosphoserine aminotransferase (serC) (PSAT)**
  P02753                                                                                                               3                                       0.01195        1.5216            CMR-N                    TKI-N                   Plasma retinol-binding protein precursor (PRBP)
  P76159                                                                                                               1                                       0.00538        1.7156            TKI-N                    CMR-Y                   Probable lysozyme from lambdoid prophage Qin
  **O67024**                                                                                                           **1**                                   **0.03110**    **Infinity**      **CMR-Y**                **TKI-N**               **Probable peroxiredoxin**
  P07737                                                                                                               2                                       0.00870        1.8459            CMR-Y                    CMR-N                   Profilin I
  **P00536**                                                                                                           **2**                                   **0.00697**    **1.5076**        **TKI-N**                **CMR-N**               **Proto-oncogene serine/threonine-protein kinase mos**
  P45604                                                                                                               1                                       0.00021        1.9033            CMR-N                    CMR-Y                   PTS system, N-acetylglucosamine-specific EIIABC component
  **Q59482**                                                                                                           **1**                                   **0.00519**    **4.2028**        **CMR-Y**                **TKI-N**               **Purine nucleoside phosphorylase (deoD)**
  **P55429**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **1**                                   **0.00004**    **2.5979**        **CMR-N**                **CMR-Y**               **Putative integrase/recombinase Y4EF**
  Q9AB80                                                                                                               3                                       0.00001        1.5354            TKI-Y                    CMR-Y                   Putative outer membrane protein CC0351 precursor
  Q9X480                                                                                                               2                                       0.00113        1.8668            CMR-N                    CMR-Y                   Putative signal peptide peptidase sppA
  P34443                                                                                                               3                                       0.02905        2.3131            CMR-Y                    TKI-Y                   Ras-like protein F54C8.5
  P34295                                                                                                               2                                       0.02474        1.4695            TKI-Y                    CMR-N                   Regulator of G protein signaling rgs-1
  Q9CG17[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00003        1.7092            CMR-Y                    TKI-N                   Ribonuclease HII (EC 3.1.26.4) (RNase HII)
  P**56566**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **2**                                   **0.00478**    **3.4601**        **TKI-N**                **CMR-N**               **S100 calcium-binding protein A3 (S-100E protein)**
  P12346[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 2                                       0.00000        2.4638            TKI-Y                    TKI-N                   Serotransferrin precursor (Siderophilin) (Beta-1-metal-binding globulin)
  P**19134**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **11**                                  **0.00347**    **2.2136**        **TKI-N**                **CMR-N**               **Serotransferrin precursor (Siderophilin)** (Beta-1-metal-binding globulin)
  P02787                                                                                                               44                                      0.00574        1.4954            CMR-Y                    CMR-N                   Serotransferrin precursor (Siderophilin) (Beta-1-m-b-g)
  **P02769**[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                             **5**                                   **0.00003**    **2.4650**        **TKI-Y**                **CMR-N**               **Serum albumin precursor (Allergen Bos d 6)**
  **Q28522**                                                                                                           **7**                                   **0.04108**    **2.6927**        **CMR-Y**                **TKI-N**               **Serum albumin precursor (Fragment)**
  **P49065**[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"},[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}              **2**                                   **0.00016**    **6.1150**        **CMR-N**                **TKI-Y**               **Serum albumin precursor**
  P27169[a](#tfn1-ijo-49-03-0913){ref-type="table-fn"},[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                  3                                       0.00416        2.1032            TKI-Y                    TKI-N                   Serum paraoxonase/arylesterase 1 (EC 3.1.1.2)
  Q9CES7[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 1                                       0.00006        2.0972            TKI-Y                    TKI-N                   Shikimate 5-dehydrogenase (EC 1.1.1.25)
  P29950[b](#tfn2-ijo-49-03-0913){ref-type="table-fn"}                                                                 2                                       0.00297        2.6116            CMR-Y                    TKI-Y                   Uracil-DNA glycosylase (EC 3.2.2.-) (UDG) (Fragment)
  P02774                                                                                                               24                                      0.00013        1.9884            CMR-Y                    TKI-N                   Vitamin D-binding protein precursor (DBP) (VDB)
  **P73069**                                                                                                           **1**                                   **0.00765**    **1.8377**        **CMR-N**                **CMR-Y**               **Ycf48-like protein**

Fifty-four differentially expressed proteins that were common between the two body fluid compartments (i.e. the 164 and 138 datasets from PBP and BMP respectively) as described in [Fig. 4](#f4-ijo-49-03-0913){ref-type="fig"}. This set of 54 proteins was then used in the unsupervised hierarchical clustering analysis as shown in [Fig. 7](#f7-ijo-49-03-0913){ref-type="fig"}. The proteins that are in bold in part A are also identified in BMP samples.

Sixty-four significantly differentially expressed proteins (\>1.5- to ∞-fold change, P\<0.05) between MMR and No-MMR sample groups used for the generation of dendrogram in [Fig. 3](#f3-ijo-49-03-0913){ref-type="fig"}. These proteins predict accurately patients with MMR vs. No-MMR patients using unsupervised Hierarchical Cluster Analysis. (Due to resolution problem, the list was cropped from the dendrogram plot). The proteins that are in bold in part B are also identified in PBP samples.
